Vol 17, No 4 2019
Launched in 2003, the Kidney Cancer Journal serves as the most comprehensive, peer-reviewed resource of information for physicians on the diagnosis and treatment of renal cell carcinoma and all of its tumor types. Published quarterly and guided by a Medical Advisory Board and an Editorial Advisory Board of leading investigators and thought leaders involved in pivotal clinical trials, Kidney Cancer Journal and its International Edition focus on the impact of translational research in oncology and urology.
Reviewing new data in the peer-reviewed medical literature, presenting case histories, and evaluating the merits of bench research, the journal offers an in-depth analysis of trends affecting patient care. Kidney Cancer Journal is the official journal of the Kidney Cancer Association and provides Continuing Medical Education credit in association with City of Hope National Medical Center, Duarte, California. Through its review of manuscript submissions by the Medical Advisory Board and Editorial Advisory Board, the journal seeks to provide the most reliable, authoritative, and scientifically rigorous information available to physicians involved in the management of renal cancer. This audience includes medical oncologists, hematologist-oncologists, and urologists.
With the advisory boards serving as a touchstone for the latest information on new drug development, the journal also alerts its readers to the relevance of ongoing clinical trials, the availability of trial enrollment, the protocols of such research, and the progress made toward the approval of new agents undergoing study. As part of its mission to inform its readership, the journal also reports on data presented at major medical meetings, including the Scientific Sessions of the American Society of Clinical Oncology, the American Urological Association and the International Symposia of the Kidney Cancer Association.
Aims and Scope
Kidney Cancer Journal is the official Journal of the Kidney Cancer Association. The objective of KCJ is to serve as the most comprehensive, peer-reviewed resource of information for physicians on the diagnosis and treatment of renal cell carcinoma and its tumor types. KCJ supports the mission of the Kidney Caner Association by facilitating the knowledge transfer, contributing to cancer prevention, early detection, diagnosis, and cure of kidney cancer. KCJ publishes original articles, reviews, clinical case studies as well as letters to the editor.
Kidney Cancer Journal is the only peer-reviewed medical journal and most comprehensive source of scientific information focusing exclusively on renal cell carcinoma. In addition, special reports and supplements covering ASCO meeting and highlights from the annual International Kidney Cancer Association Meeting also published. KCJ is distributed as a complimentary professional service to approximately 12,300 physicians, including all medical oncologists and targeted urologists. KCJ utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 oncologists/physicians who are leading investigators in this field. Archives available through the KCA’s website at www.kidneycancer.org
Copyright © 2020